The Goldman Sachs technology M&A team, led by Sam Britton, has cashed in on its software focus and decades of experience to dominate 2019's biggest deals.Technologyread more
American small and medium-size companies that rely on China are scrambling to adjust their business plans in response to the escalating trade war.Traderead more
Here are the products that stand to be the most affected by China's new tariffs on $75 billion worth of U.S. goods.Marketsread more
The summit comes amid fears over a global economic slowdown, and U.S. tensions over trade allies, Iran and Russia.Politicsread more
The world's second biggest economy is past a point where it cannot ignore its enormous debt anymore, according to an analyst.China Economyread more
Carl Medlock used to work at Tesla. Now he's one of the few people in the U.S. that can fix the company's original Roadster electric vehicles.Technologyread more
Trump does have some powerful tools that would not require approval from U.S. Congress.Politicsread more
Stocks dropped after Donald Trump ordered that U.S. manufacturers find alternatives to their operations in China.US Marketsread more
As demand for lab monkeys continues to rise, U.S. scientists are reporting delays in research projects because they can't obtain enough animals, according to the National...Politicsread more
The European Union will respond in kind if the U.S. imposes tariffs on France over digital tax plan, EU chief Donald Tusk told G-7.Technologyread more
Trump said he will raise tariffs on $250 billion in Chinese goods to 30% and hike duties on another $300 billion in products to 15%.Politicsread more
Theranos has withdrawn the results of all blood tests run on its Edison device in 2014 and 2015, The Wall Street Journal reported Wednesday, citing a person familiar with the matter.
According to the report, Theranos has informed the Centers for Medicare and Medicaid Services of its decision to issue corrected blood-test reports to doctors and patients, canceling the results in some cases and revising others.
Theranos' reputation has been based on providing fast, accurate and affordable blood testing, using its Edison machine, which employs smaller needles and tubes than traditional blood-testing devices.
But the company, valued at more than $9 billion, has come under scrutiny after media reports questioned the accuracy of the proprietary test methods.
A particular blood-coagulation test was deemed in January by the Centers for Medicare and Medicaid Service to put patients in "immediate jeopardy," according to the WSJ report.
According to the WSJ, Theranos' latest move was aimed at convincing the agency to not impose strict sanctions.
"Excellence in quality and patient safety is our top priority and we've taken comprehensive corrective measures to address the issues CMS raised in their observations. As these matters are currently under review, we have no further comment at this time," a Theranos spokesperson said in response to the WSJ report.
You can read the full WSJ report here
- Anita Balakrishnan contributed to this article
- Follow CNBC International on and Facebook.